Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights
November 15, 2018 16:07 ET
|
Equillium, Inc.
Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation of Phase 1b/2 Trial of EQ001 in Acute Graft-Versus-Host Disease ...
Equillium Announces Pricing of Initial Public Offering
October 12, 2018 08:25 ET
|
Equillium, Inc.
LA JOLLA, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune...